Yeah

... into the first line, understandably so.

You know, um, everyone wants to leverage the immunotherapy benefit and the durability of those benefits and survival benefits of that approach.

But, uh, I think one of the things that we have to highlight here that's so important is the unmet need of second line and beyond.

You know, we have no true standards in the, in, in these settings, and, uh, this is really where patients require, you know, more investig- um, more investigational agents and more effective therapies.

Um, so this, this was just following that kind of development strategy that all agents go through, which is let's test and see the safety and efficacy in that, in that second line and beyond, and depending upon that signal, figure out what the strategy is for development.

And so, um, and indeed, you know, when you look at the two schedules, one of the, you know, some of the bottom line observations here was that the every other week was better tolerated, much lower, uh, event rates, um, in terms of grade three or serious adverse events rates, and so that's the schedule that was identified.

Yeah